Abstract:Objective To evaluate the efficacy and safety of low-dose cyclosporine A (CsA) combined with low-dose prednisone as induction therapy for patients with idiopathic membranous nephropathy (IMN) and compare with those of cyclophosphamide (CTX) combined with high-dose prednisone.Methods A prospective observational cohort study in 31 nephrotic patients with IMN was conducted.In CTX group,patients were treated with cyclophosphamide (oral 100 mg/d,accumulation about 8 g) combined with prednisone (0.6-1.0 mg·kg~(-1)·d~(-1),tapered after 2-3 months).In CsA group,initial dose of CsA was 1.0-1.5 mg·kg~(-1)·d~(-1) combined with prednisone 0.15-0.50 mg·kg~(-1)·d~(-1)[(0.33±0.20) mg·kg~(-1)·d~(-1),tapered after 3 months].The dose of CsA was added gradually according to efficacy and the highest dose of cyclosporine was ≤2.5 mg·kg~(-1)·d~(-1).Clinical parameters (urinary protein,serum albumin and serum creatinine) and adverse effects were estimated before and after therapy.ResultsIn CTX group,twenty patients had been followed-up for (48±22) weeks and their remission was observed in 13 patients (65%,complete remission 6,partial remission 7).Nineteen patients were recruited in CsA group,including 8 patients who either had no response or relapsed after CTX therapy.In CsA group,two patients discontinued CsA therapy due to severe uncontrolled hypertension;the effective dose of CsA for remission was (2.1±0.4) mg·kg~(-1)·d~(-1) (1.5-2.5 mg·kg~(-1)·d~(-1));mean trough concentration of CsA was (92.5±23.5) μg/L (58-124 μg/L);remission was observed in 12 patients (70%,complete remission 6,partial remission 6) over a period of (44±15) weeks.There was no significant difference of remission rate between two groups.Liver dysfunction was common adverse effects during CTX therapy.Many adverse effects (increase of serum creatinine,hypertension,gum hyperplasia and hyperuricemia) occurred during CsA therapy,but could be easily controlled.Conclusions Low-dose CsA combined with low-dose prednisone has similar efficacy and safety to CTX combined with high-dose prednisone for majority of patients with IMN,including refractory patients to CTX regimens.Many adverse effects occur during CsA therapy,but can be easily controlled.

Study on the Pharmacodynamics of Low Molecular Weight Chitosan - Prednisolone Conjugate

Enhanced Steroid Therapy In Adult Minimal Change Nephrotic Syndrome: A Systematic Review And Meta-Analysis

Mycophenolate mofetil combined with low dose prednisone in the treatment for adults with minimal change nephrotic syndrome and concomitant HBsAg positive

The combination of mycophenolate mofetil with corticosteroids induces remission of Henoch-Schönlein purpura nephritis.

Molecular Weight-Dependent Immunostimulative Activity of Low Molecular Weight Chitosan Via Regulating NF-κB and AP-1 Signaling Pathways in RAW264.7 Macrophages

Intravenous methylprednisolone for nephrotic syndrome with minimal change lesions in adults: a randomized controlled trial

[Study on a New Antarthritic Injection--o-carboxymethyl Chitosan].

Tacrolimus As a Steroid-Sparing Agent for Adults with Steroid-Dependent Minimal Change Nephrotic Syndrome

[Conference at the Salpêtrière. 6 July 1983. Progressive paralysis of the cranial nerves and cerebellar instability].

Preparation of chitosan/sodium lignosulfonate/Ag NPs: A potent and green bio-nanocomposite for the treatment of glucocorticoid induced osteoporosis in rats

Effect of soluble and insoluble fibers within the in vitro fermentation of chicory root pulp by human gut bacteria.

Visualized podocyte-targeting and focused ultrasound responsive glucocorticoid nano-delivery system against immune-associated nephropathy without glucocorticoid side effect

Chondroitin sulfate and L-Cysteine conjugate modified cationic nanostructured lipid carriers: Pre-corneal retention, permeability, and related studies for dry eye treatment

Development and assessment of the efficacy and safety of human lung-targeting liposomal methylprednisolone crosslinked with nanobody

Studies on Anti-Hepatocarcinoma Effect, Pharmacokinetics and Tissue Distribution of Carboxymethyl Chitosan Based Norcantharidin Conjugates.

The Use of Data Mining for Obtaining Deeper Insights into the Fabrication of Prednisolone-Loaded Chitosan Nanoparticles

Immuno-Nanoparticles Developed Using Dexamethasone and Captopril Co-Loaded PLGA Improve Glomerulonephritis Through Modulating Macrophage Polarization

Preparation of Low Molecular Weight Chitosan and Its Efficiency Both in Vitro and in Vivo

Low-Dose Cyclosporine Treatment in Chinese Nephrotic Patients with Idiopathic Membranous Nephropathy: an Uncontrolled Study with Prospective Follow-Up

Preliminary observation of low-dose cyclosporine A combined with low-dose prednisone in the treatment of patients with idiopathic membranous nephropathy

Synthesis and in vitro evaluation of methotrexate conjugated O,N-carboxymethyl chitosan via peptidyl spacers